Shihui Guo

Dr. Shihui Guo

Department of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
YGYongsheng Gao
Yongsheng Gao
ASApoorva Sarode
Apoorva Sarode
NKNikolaos Kokoroskos
Nikolaos Kokoroskos
AUAnvay Ukidve
Anvay Ukidve
ZZZongmin Zhao
Zongmin Zhao
SMSamir Mitragotri
Samir Mitragotri
The study describes a synthetic hemostatic agent that can be intravenously injected to reduce internal hemorrhage.

5 January 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
WZWandi Zhu
Wandi Zhu
SGShihui Guo
Shihui Guo
MHMax Homilius
Max Homilius
CNCissy Nsubuga
Cissy Nsubuga
SWShane H. Wright
Shane H. Wright
CMCalum A. MacRae
Calum A. MacRae
Hematopoietic cell selection based on PIEZO1 expression drives thrombosis risk in type 2 diabetes.

14 September 2009 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
SGShihui Guo
Shihui Guo
XSXiaoli Shi
Xiaoli Shi
FYFeng Yang
Feng Yang
LCLiqing Chen
Liqing Chen
EMEdward J. Meehan
Edward J. Meehan
MHMingdong Huang
Mingdong Huang
Lysophospholipids play important roles in cellular signal transduction and are implicated in many biological processes, including tumorigenesis, angiogenesis, immunity, atherosclerosis, arteriosclerosis, cancer and neuronal survival. The intracellular transport of lysophospholipids is through FA (fatty acid)-binding protein. Lysophospholipids are also found in the extracellular space. However, the transport mechanism of lysophospholipids in the extracellular space is unknown. HSA (human serum albumin) is the most abundant carrier protein in blood plasma and plays an important role in determining the absorption, distribution, metabolism and excretion of drugs. In the present study, LPE (lysophosphatidylethanolamine) was used as the ligand to analyse the interaction of lysophospholipids with HSA by fluorescence quenching and crystallography. Fluorescence measurement showed that LPE binds to HSA with a Kd (dissociation constant) of 5.6 μM. The presence of FA (myristate) decreases this binding affinity (Kd of 12.9 μM). Moreover, we determined the crystal structure of HSA in complex with both myristate and LPE and showed that LPE binds at Sudlow site I located in subdomain IIA. LPE occupies two of the three subsites in Sudlow site I, with the LPE acyl chain occupying the hydrophobic bottom of Sudlow site I and the polar head group located at Sudlow site I entrance region pointing to the solvent. This orientation of LPE in HSA suggests that HSA is capable of accommodating other lysophospholipids and phospholipids. The study provides structural information on HSA–lysophospholipid interaction and may facilitate our understanding of the transport and distribution of lysophospholipids.

1 December 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
WSWolfgang Skala
Wolfgang Skala
DUDaniel T. Utzschneider
Daniel T. Utzschneider
VMViktor Magdolen
Viktor Magdolen
MDMekdes Debela
Mekdes Debela
SGShihui Guo
Shihui Guo
Peter GoettigPeter Goettig
Peter Goettig
Human kallikrein-related peptidase 2 (KLK2) is a tryptic serine protease predominantly expressed in prostatic tissue and secreted into prostatic fluid, a major component of seminal fluid. Most likely it activates and complements chymotryptic KLK3 (prostate-specific antigen) in cleaving seminal clotting proteins, resulting in sperm liquefaction. KLK2 belongs to the “classical” KLKs 1–3, which share an extended 99- or kallikrein loop near their non-primed substrate binding site. Here, we report the 1.9 Å crystal structures of two KLK2-small molecule inhibitor complexes. In both structures discontinuous electron density for the 99-loop indicates that this loop is largely disordered. We provide evidence that the 99-loop is responsible for two biochemical peculiarities of KLK2, i.e. reversible inhibition by micromolar Zn2+ concentrations and permanent inactivation by autocatalytic cleavage. Indeed, several 99-loop mutants of KLK2 displayed an altered susceptibility to Zn2+, which located the Zn2+ binding site at the 99-loop/active site interface. In addition, we identified an autolysis site between residues 95e and 95f in the 99-loop, whose elimination prevented the mature enzyme from limited autolysis and irreversible inactivation. An exhaustive comparison of KLK2 with related structures revealed that in the KLK family the 99-, 148-, and 220-loop exist in open and closed conformations, allowing or preventing substrate access, which extends the concept of conformational selection in trypsin-related proteases. Taken together, our novel biochemical and structural data on KLK2 identify its 99-loop as a key player in activity regulation.

6 August 2014 in Biological Chemistry
Verified
Journal Article
Open access
PDF file
SGShihui Guo
Shihui Guo
WSWolfgang Skala
Wolfgang Skala
VMViktor Magdolen
Viktor Magdolen
HBHans Brandstetter
Hans Brandstetter
Peter GoettigPeter Goettig
Peter Goettig
Most kallikrein-related peptidases (KLKs) are N-glycosylated with N-acetylglucosamine2-mannose9 units at Asn-Xaa-Ser/Thr sequons during protein synthesis and translocation into the endoplasmic reticulum. These N-glycans are modified in the Golgi machinery, where additional O-glycosylation at Ser and Thr takes place, before exocytotic release of the KLKs into the extracellular space. Sequons are present in all 15 members of the KLKs and comparative studies for KLKs from natural and recombinant sources elucidated some aspects of glycosylation. Although glycosylation of mammalian KLKs 1, 3, 4, 6, and 8 has been analyzed in great detail, e.g., by crystal structures, the respective function remains largely unclear. In some cases, altered enzymatic activity was observed for KLKs upon glycosylation. Remarkably, for KLK3/PSA, changes in the glycosylation pattern were observed in samples of benign prostatic hyperplasia and prostate cancer with respect to healthy individuals. Potential functions of KLK glycosylation in structural stabilization, protection against degradation, and activity modulation of substrate specificity can be deduced from a comparison with other glycosylated proteins and their regulation. According to the new concept of protein sectors, glycosylation distant from the active site might significantly influence the activity of proteases. Novel pharmacological approaches can exploit engineered glycans in the therapeutical context.

1 January 2016 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SGShihui Guo
Shihui Guo
WSWolfgang Skala
Wolfgang Skala
VMViktor Magdolen
Viktor Magdolen
PBPeter Briza
Peter Briza
MBMartin L. Biniossek
Martin L. Biniossek
Peter GoettigPeter Goettig
Peter Goettig
Human kallikrein-related peptidase 2 (KLK2) is a key serine protease in semen liquefaction and prostate cancer together with KLK3/prostate-specific antigen. In order to decipher the function of its potential N-glycosylation site, we produced pro-KLK2 in Leishmania tarentolae cells and compared it with its non-glycosylated counterpart from Escherichia coli expression. Mass spectrometry revealed that Asn-95 carries a core glycan, consisting of two GlcNAc and three hexoses. Autocatalytic activation was retarded in glyco-pro-KLK2, whereas the activated glyco-form exhibited an increased proteolytic resistance. The specificity patterns obtained by the PICS (proteomic identification of protease cleavage sites) method are similar for both KLK2 variants, with a major preference for P1-Arg. However, glycosylation changes the enzymatic activity of KLK2 in a drastically substrate-dependent manner. Although glyco-KLK2 has a considerably lower catalytic efficiency than glycan-free KLK2 toward peptidic substrates with P2-Phe, the situation was reverted toward protein substrates, such as glyco-pro-KLK2 itself. These findings can be rationalized by the glycan-carrying 99-loop that prefers to cover the active site like a lid. By contrast, the non-glycosylated 99-loop seems to favor a wide open conformation, which mostly increases the apparent affinity for the substrates (i.e. by a reduction of Km). Also, the cleavage pattern and kinetics in autolytic inactivation of both KLK2 variants can be explained by a shift of the target sites due to the presence of the glycan. These striking effects of glycosylation pave the way to a deeper understanding of kallikrein-related peptidase biology and pathology.